Branding Gene Genome 
pharmaphorum
APRIL 5, 2022
The team has focused initially on non-small cell lung cancer (NSCLC), the most common form of lung cancer, but say the same principles could be applied to other tumour types, and combined with other testing approaches like genomics to inform treatment decisions.
pharmaphorum
MARCH 19, 2021
Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves 1. Scientists have identified responsible genes for approximately 50% of the estimated 7000 rare diseases 2. How do you find rare disease patients?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 23, 2021
Berlin, March 23, 2021 – Bayer announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi , for the treatment of Neurotrophic Tyrosine Receptor Kinase ( NTRK ) fusion-positive advanced or recurrent solid tumors. Fields, M.D.,
Pharma Marketing Network
DECEMBER 21, 2020
Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.
The Pharma Data
SEPTEMBER 29, 2021
Data from four distinct analyses for Vitrakvi (larotrectinib) showcase its sustained clinical benefit for patients with solid tumors harboring an NTRK gene fusion (also referred to as TRK fusion cancer). About TRK Fusion Cancer TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing a chimeric TRK protein.
The Pharma Data
APRIL 6, 2021
Israel and Taiwan under the brand name Aliqopa. While local labels might differ, the product is approved for adult and pediatric patients with solid tumors that harbor a NTRK gene fusion and have no satisfactory alternative treatments. Vitrakvi is approved in multiple countries around the world, including the U.S., EU, UK and Japan.
The Pharma Data
APRIL 11, 2023
Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread. The Bayer brand stands for trust, reliability and quality throughout the world. billion euros. billion euros.
Expert insights. Personalized for you.
67 
Let's personalize your content